An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: BMS-986165
Other: Placebo
Drug: Apremilast

Registration Number: NCT03611751

Lead Sponsor: Bristol-Myers Squibb

Brief Summary: The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 1020

Inclusion Criteria

Plaque psoriasis for at least 6 months
Moderate to severe disease
Candidate for phototherapy or systemic therapy

Exclusion Criteria

Other forms of psoriasis
History of recent infection
Prior exposure to BMS-986165 or active comparator

Other protocol defined inclusion/exclusion criteria could apply

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
BMS-986165	BMS-986165	BMS-986165 oral administration
Placebo	Placebo	Placebo oral administration
Active comparator	Apremilast	Active comparator oral administration

Primary Outcome Measures

Name	Time	Method
The Number of Participants With a Static Physician's Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (sPGA 0/1)	Week 16	The sPGA is a 5-point scale average assessment of all psoriatic lesions graded for erythema, scale, and induration. The sPGA measure determines psoriasis severity at a single point in time (without taking into account the baseline disease condition) as: clear (0), almost clear (1), mild (2), moderate (3), or severe (4). The average of the 3 scales, which is rounded to the nearest whole number, is the final sPGA score. The higher sPGA score denotes to more severe disease activity. sPGA 0/1 is the response as a number of participants who experience a sPGA score that determines psoriasis severity as 0 or 1 with at least a 2-point improvement from baseline using the non-responder imputation (NRI) method. Non-responder imputation (NRI) will be used for participants who: Discontinue treatment or study prior to Week 16 or who have missing Week 16 endpoint data for any reason.
The Number of Participants Who Achieve a 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (PASI 75)	Baseline and Week 16	The Psoriasis Area and Severity Index (PASI) is a quantitative rating scale for measuring the severity of psoriatic lesions based on area coverage and plaque appearance. The PASI is a measure of the average erythema (redness), infiltration (thickness), and desquamation (scaling) of psoriatic skin lesions (each graded on a 0-4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the response as a number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method. Baseline is defined as the measurement at the randomization visit (Week 0). Non-responder imputation (NRI) will be used for participants who: Discontinue treatment or study prior to Week 16 or who have missing Week 16 endpoint data for any reason.

Secondary Outcome Measures

Name	Time	Method
The Number of Participants With a Dermatology Life Quality Index (DLQI) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (DLQI 0/1)	Week 16	The DLQI is a participant-reported quality of life index which consists of 10 questions concerning how much skin problems affect symptoms and feelings, daily activities, leisure, work, school, personal relationships, and treatment during the last week. Each question is scored on a scale of 0 to 3 where 0 = not at all, 1 =a little, 2 = a lot, or 3 = very much. The scores are summed, giving a range from 0 (no impairment of life quality) to 30 (maximum impairment). DLQI 0/1 is the number of participants with a score of 0 or 1 among participants with a baseline DLQI score ≥2. Non-responder imputation (NRI) will be used for participants who: Discontinue treatment or study prior to Week 16 or who have missing Week 16 endpoint data for any reason.
The Number of Participants Who Achieve a 90% Improvement From Baseline in the Psoriasis Area and Severity Index Score at Week 16 (PASI 90)	Baseline and Week 16	The Psoriasis Area and Severity Index (PASI) is a quantitative rating scale for measuring the severity of psoriatic lesions based on area coverage and plaque appearance. The PASI is a measure of the average erythema (redness), infiltration (thickness), and desquamation (scaling) of psoriatic skin lesions (each graded on a 0-4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 90 is the response as a number of participants who experience at least a 90% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method. Baseline is defined as the measurement at the randomization visit (Week 0). Non-responder imputation (NRI) will be used for participants who: Discontinue treatment or study prior to Week 16 or who have missing Week 16 endpoint data for any reason.
The Number of Participants Who Achieve a 100% Improvement From Baseline in the Psoriasis Area and Severity Index Score at Week 16 (PASI 100)	Baseline and Week 16	The Psoriasis Area and Severity Index (PASI) is a quantitative rating scale for measuring the severity of psoriatic lesions based on area coverage and plaque appearance. The PASI is a measure of the average erythema (redness), infiltration (thickness), and desquamation (scaling) of psoriatic skin lesions (each graded on a 0-4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 100 is the response as a number of participants who experience at least a 100% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method. Baseline is defined as the measurement at the randomization visit (Week 0). Non-responder imputation (NRI) will be used for participants who: Discontinue treatment or study prior to Week 16 or who have missing Week 16 endpoint data for any reason.
The Number of Participants With a Static Physician Global Assessment Score of 0 at Week 16 (sPGA 0)	Week 16	The sPGA is a 5-point scale average assessment of all psoriatic lesions graded for erythema, scale, and induration. The sPGA measure determines psoriasis severity at a single point in time (without taking into account the baseline disease condition) as: clear (0), almost clear (1), mild (2), moderate (3), or severe (4). The average of the 3 scales, which is rounded to the nearest whole number, is the final sPGA score. sPGA 0 is the response as a number of participants who experience a sPGA score that determines psoriasis severity as 0 using the non-responder imputation (NRI) method. Non-responder imputation (NRI) will be used for participants who: Discontinue treatment or study prior to Week 16 or who have missing Week 16 endpoint data for any reason.
Change From Baseline in Psoriasis Symptoms and Signs Diary (PSSD) Symptom Score at Week 16	Baseline and Week 16	PSSD assesses the severity of 5 symptoms (itch, pain, stinging, burning, skin tightness) and 6 participant-observed signs (skin dryness, cracking, scaling, shedding or flaking, redness, bleeding). The severity of each item is rated on an 11-point numeric rating scale ranging from 0 (absent) to 10 (worst imaginable). Both symptom and sign scores are derived by averaging the questions and multiplying by 10. A total PSSD score ranging 0-100 will be derived from taking the average of the symptom and sign scores. 0 represents the least severe symptom/sign and 100 represents the most severe. Baseline is defined as the measurement at the randomization visit (Week 0). A modified observation carried forward (mBOCF) approach will be used for missing data. The baseline observation will be carried forward for participants who discontinue study treatment for all analysis weeks after the assessment time point of discontinuation due to lack of efficacy and AEs.
Psoriasis Symptoms and Signs Diary (PSSD) Symptom Score of 0 at Week 16	Week 16	Psoriasis Symptoms and Signs Diary (PSSD) is an 11-item participant-reported instrument that assesses severity of symptoms and participant-observed signs commonly associated in plaque psoriasis. The PSSD assesses severity of 5 symptoms (itch, pain, stinging, burning, skin tightness) and 6 participant-observed signs (skin dryness, cracking, scaling, shedding or flaking, redness, bleeding) using 0 to 10 numerical ratings. The severity of each item is rated on an 11-point numeric rating scale ranging from 0 (absent) to 10 (worst imaginable) where the symptoms summary score is derived from the average of the scores. A higher score indicates more severe disease. PSSD 0 is the response as a number of participants who experience a PSSD symptom score that determines psoriasis severity as 0 among participants with a baseline PSSD symptom score \>= 1 using the non-responder imputation (NRI) method.
The Number of Participants With a Scalp Specific Physician's Global Assessment (Ss-PGA) Score 0 or 1 at Week 16 (Ss-PGA 0/1)	Week 16	The scalp specific Physician's Global Assessment (ss-PGA) evaluates scalp lesions in terms of clinical signs of redness, thickness, and scaliness and scored on the following 5-point ss-PGA scale: 0 = absence of disease, 1 = very mild disease, 2 = mild disease, 3 = moderate disease, 4 = severe disease. ss-PGA 0/1 is the response as a number of participants who experience a ss-PGA score of 0 or 1 with at least a 2-point improvement from baseline among participants with a baseline ss-PGA score ≥3 . Non-responder imputation (NRI) will be used for participants who: Discontinue treatment or study prior to Week 16 or who have missing Week 16 endpoint data for any reason.
The Number of Participants With a Physician Global Assessment- Fingernails (PGA-F) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (PGA-F 0/1)	Week 16	The Physician Global Assessment- Fingernails (PGA-F) evaluates the overall condition of the fingernails and is rated on a 5-point scale:0 = clear, 1 = minimal, 2 = mild, 3 = moderate, and 4 = severe. PGA-F 0/1 is the response as a number of participants with a PGA-F score of 0 or 1 with at least a 2-point improvement from baseline among participants with a baseline PGA-F score \>=3. Non-responder imputation (NRI) will be used for participants who: Discontinue treatment or study prior to Week 16 or who have missing Week 16 endpoint data for any reason.
The Number of Participants With a Palmoplantar Physician's Global Assessment (Pp-PGA) Score of 0 or 1 at Week 16 (Pp-PGA 0/1)	Week 16	The palmoplantar Physician's Global Assessment (pp-PGA) score evaluates palmoplantar (including finger and toe surfaces) psoriasis lesions based on overall severity by investigator, then scored on the following 5-point scale: 0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; and 4 = severe. pp-PGA 0/1 is the number of participants with a score of 0 or 1 among participants with a baseline pp-PGA score ≥ 3.
The Number of Participants Who Achieve a 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Apremilast at Week 16 (PASI 75)	Baseline and Week 16	The Psoriasis Area and Severity Index (PASI) is a quantitative rating scale for measuring the severity of psoriatic lesions based on area coverage and plaque appearance. The PASI is a measure of the average erythema (redness), infiltration (thickness), and desquamation (scaling) of psoriatic skin lesions (each graded on a 0-4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the response as a number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method. Baseline is defined as the measurement at the randomization visit (Week 0). Non-responder imputation (NRI) will be used for participants who: Discontinue treatment or study prior to Week 16 or who have missing Week 16 endpoint data for any reason.
The Number of Participants With a Static Physician Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Apremilast at Week 16 (sPGA 0/1)	Week 16	The sPGA is a 5-point scale average assessment of all psoriatic lesions graded for erythema, scale, and induration. The sPGA measure determines psoriasis severity at a single point in time (without taking into account the baseline disease condition) as: clear (0), almost clear (1), mild (2), moderate (3), or severe (4). The average of the 3 scales, which is rounded to the nearest whole number, is the final sPGA score. sPGA 0/1 is the number of participants with a sPGA score of 0 or 1 with at least a 2-point improvement from baseline. Non-responder imputation (NRI) will be used for participants who: Discontinue treatment or study prior to Week 16 or who have missing Week 16 endpoint data for any reason.
Time to Relapse Until Week 52 Among Week 24 PASI 75 Responders	From Week 24 to Week 52 (up to approximately 28 weeks)	Relapse is defined as 50% loss or greater of Week 24 PASI percent improvement from baseline. The PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0-4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity.
The Number of Participants With a Static Physician Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Apremalist at Week 24 (sPGA 0/1)	Week 24	The sPGA is a 5-point scale average assessment of all psoriatic lesions graded for erythema, scale, and induration. The sPGA measure determines psoriasis severity at a single point in time (without taking into account the baseline disease condition) as: clear (0), almost clear (1), mild (2), moderate (3), or severe (4). The average of the 3 scales, which is rounded to the nearest whole number, is the final sPGA score. sPGA 0/1 is the number of participants with a sPGA score of 0 or 1. Non-responder imputation (NRI) will be used for participants who: Discontinue treatment or study prior to Week 24 or who have missing Week 24 endpoint data for any reason.
The Number of Participants Who Achieve a 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Apremalist at Week 24 (PASI 75)	Baseline and Week 24	The Psoriasis Area and Severity Index (PASI) is a quantitative rating scale for measuring the severity of psoriatic lesions based on area coverage and plaque appearance. PASI is a measure of the average erythema (redness), infiltration (thickness), and desquamation (scaling) of psoriatic skin lesions (each graded on a 0-4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the response as a number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method. Baseline is defined as the measurement at the randomization visit (Week 0). Non-responder imputation (NRI) will be used for participants who: Discontinue treatment or study prior to Week 24 or who have missing Week 24 endpoint data for any reason.
The Number of Participants Who Achieve a 90% Improvement From Baseline in the Psoriasis Area and Severity Index Score in Participants Receiving BMS-986165 Compared to Apremilast at Week 24 (PASI 90)	Baseline and week 24	The Psoriasis Area and Severity Index (PASI) is a quantitative rating scale for measuring the severity of psoriatic lesions based on area coverage and plaque appearance. PASI is a measure of the average erythema (redness), infiltration (thickness), and desquamation (scaling) of psoriatic skin lesions (each graded on a 0-4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 90 is the response as a number of participants who experience at least a 90% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method. Baseline is defined as the measurement at the randomization visit (Week 0). Non-responder imputation (NRI) will be used for participants who: Discontinue treatment or study prior to Week 24 or who have missing Week 24 endpoint data for any reason.

Trial Locations

Locations (198): Interspond - Savin Medical Group
🇺🇸
Miami Lakes, Florida, United States
Tufts Medical Center
🇺🇸
Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center
🇺🇸
Boston, Massachusetts, United States
PMG Research of Cary
🇺🇸
Cary, North Carolina, United States
DermEdge
🇨🇦
Mississauga, Ontario, Canada
York Dermatology Clinic and Research Centre
🇨🇦
Mississauga, Ontario, Canada
University of California San Diego Health Systems
🇺🇸
San Diego, California, United States
Synexus - Cincinnati
🇺🇸
Cincinnati, Ohio, United States
Progressive Clinical Research - San Antonio
🇺🇸
San Antonio, Texas, United States
LA Universal Research Center
🇺🇸
Los Angeles, California, United States
Interspond - Long Beach Clinical Trials
🇺🇸
Long Beach, California, United States
The Kirklin Clinic of UAB Hospital
🇺🇸
Birmingham, Alabama, United States
Therapeutics Clinical Research
🇺🇸
San Diego, California, United States
Artemis Institute for Clinical Research - San Marcos
🇺🇸
San Marcos, California, United States
Dawes Fretzin Dermatology Group
🇺🇸
Indianapolis, Indiana, United States
West Coast Research
🇺🇸
San Ramon, California, United States
Washington University School of Medicine - West County Dermatology
🇺🇸
Creve Coeur, Missouri, United States
University Hospitals Case Medical Center
🇺🇸
Cleveland, Ohio, United States
Wright State Research Institute
🇺🇸
Fairborn, Ohio, United States
Paddington Testing Company
🇺🇸
Philadelphia, Pennsylvania, United States
Dermatology Clinical Research Center of San Antonio
🇺🇸
San Antonio, Texas, United States
Fremantle Dermatology
🇦🇺
Fremantle, Western Australia, Australia
Alliance Dermatology and Mohs Center - Phoenix
🇺🇸
Phoenix, Arizona, United States
Brigham Dermatology Associates
🇺🇸
Boston, Massachusetts, United States
Stamford Therapeutics Consortium
🇺🇸
Stamford, Connecticut, United States
Skin Care Research
🇺🇸
Boca Raton, Florida, United States
Health Concepts
🇺🇸
Rapid City, South Dakota, United States
Progressive Medical Research
🇺🇸
Port Orange, Florida, United States
Clinical Research Consortium - Tempe
🇺🇸
Tempe, Arizona, United States
Skin and Cancer Foundation
🇦🇺
Carlton, Victoria, Australia
Local Institution - 0183
🇵🇱
Wroclaw, Poland
ERN - Accel Research - Avail
🇺🇸
DeLand, Florida, United States
Coastal Carolina Research Center - Mount Pleasant
🇺🇸
Mount Pleasant, South Carolina, United States
Box Hill Hospital
🇦🇺
Box Hill, Victoria, Australia
Kim Papp Clinical Research
🇨🇦
Waterloo, Ontario, Canada
West Virginia University
🇺🇸
Morgantown, West Virginia, United States
Dermatology Associates of Knoxville
🇺🇸
Knoxville, Tennessee, United States
Woden Dermatology
🇦🇺
Phillip, Australian Capital Territory, Australia
Local Institution - 0246
🇩🇪
Frankfurt am Main, Germany
Azienda Ospedaliero-Universitaria Pisana Ospedale Santa Chiara
🇮🇹
Pisa, Italy
ZDROWIE OSTEO-MEDIC s.c. Lidia i Artur Racewicz, Agnieszka i Jerzy Supronik
🇵🇱
Bialystok, Poland
Centrum Kliniczno Badawcze J Brzezicki B Gornikiewicz Brzezicka Lekarze Spolka Partnerska
🇵🇱
Elblag, Poland
Veracity Clinical Research
🇦🇺
Woolloongabba, Queensland, Australia
Stratica Medical
🇨🇦
Edmonton, Alberta, Canada
Institute for Skin Advancement
🇨🇦
Calgary, Alberta, Canada
Clinical Research Solutions - Jackson
🇺🇸
Jackson, Tennessee, United States
Office of Dr. Niakosari Firouzeh
🇨🇦
North York, Ontario, Canada
CCA Medical Research
🇨🇦
Ajax, Ontario, Canada
Innovaderm Research
🇨🇦
Montreal, Quebec, Canada
Lynderm Research
🇨🇦
Markham, Ontario, Canada
Synexus Magyarorszag Egeszsegugyi Szolgaltato - Zalaegerszeg
🇭🇺
Zalaegerszeg, Hungary
GCM Medical Group
🇵🇷
San Juan, Puerto Rico
Hopital Prive dAntony
🇫🇷
Antony, France
Centre Hospitalier Universitaire de Nice Hopital lArchet
🇫🇷
Nice Cedex 3, France
Hautarztpraxis Dr. Niesmann & Dr. Othlinghaus
🇩🇪
Bochum, Germany
Niepubliczny Zaklad Opieki Zdrowotnej MED-LASER
🇵🇱
Lublin, Poland
Toronto Dermatology Centre
🇨🇦
Toronto, Ontario, Canada
Dermatology on Bloor
🇨🇦
Toronto, Ontario, Canada
ETG - Warszawa
🇵🇱
Warszawa, Poland
Dr. Isabelle Delorme
🇨🇦
Drummondville, Quebec, Canada
Josa Andras Oktatokorhaza - Szabolcs Szatmar-Bereg Megyei Onkormanyzat
🇭🇺
Nyiregyhaza, Hungary
Azienda Ospedaliero Universitaria di Bologna Policlinico SantOrsola-Malpighi
🇮🇹
Bologna, Italy
ETG - Skierniewice
🇵🇱
Skierniewice, Poland
Burke Pharmaceutical Research
🇺🇸
Hot Springs, Arkansas, United States
Marvel Clinical Research
🇺🇸
Huntington Beach, California, United States
Johnson Dermatology
🇺🇸
Fort Smith, Arkansas, United States
Associates in Research, Inc.
🇺🇸
Fresno, California, United States
Dermatology Research Associates - Los Angeles
🇺🇸
Los Angeles, California, United States
San Luis Dermatology and Laser Clinic
🇺🇸
San Luis Obispo, California, United States
Clinical Science Institute
🇺🇸
Santa Monica, California, United States
Care Access Research - Walnut Creek
🇺🇸
Walnut Creek, California, United States
Synexus - Santa Rosa
🇺🇸
Santa Rosa, California, United States
Artemis Institute for Clinical Research - San Diego
🇺🇸
San Diego, California, United States
Southern Illinois University School of Medicine
🇺🇸
Springfield, Illinois, United States
Glazer Dermatology
🇺🇸
Buffalo Grove, Illinois, United States
Synexus - Evansville South
🇺🇸
Evansville, Indiana, United States
Advanced Clinical Research - Idaho
🇺🇸
Meridian, Idaho, United States
Marietta Dermatology & The Skin Cancer Center
🇺🇸
Marietta, Georgia, United States
Shondra L. Smith, M.D.
🇺🇸
Lake Charles, Louisiana, United States
St. George Dermatology & Skin Care Centre
🇦🇺
Kogarah, New South Wales, Australia
Advanced Medical Research
🇺🇸
Lacombe, Louisiana, United States
Ora
🇺🇸
Andover, Massachusetts, United States
Holdsworth House Medical Practice
🇦🇺
Darlinghurst, New South Wales, Australia
Hamzavi Dermatology
🇺🇸
Fort Gratiot, Michigan, United States
ClinOhio Research Services
🇺🇸
Columbus, Ohio, United States
Westmead Hospital
🇦🇺
Westmead, New South Wales, Australia
Rivergate Dermatology - Main Office
🇺🇸
Goodlettsville, Tennessee, United States
The Skin Wellness Center
🇺🇸
Knoxville, Tennessee, United States
Healthcare Research Network - Hazelwood
🇺🇸
Hazelwood, Missouri, United States
Arlington Center for Dermatology
🇺🇸
Arlington, Texas, United States
Windsor Dermatology
🇺🇸
East Windsor, New Jersey, United States
Clinical Research Consortium - Las Vegas
🇺🇸
Las Vegas, Nevada, United States
Dermatology and Skin Surgery Center - Exton
🇺🇸
Exton, Pennsylvania, United States
Dermatology Consulting Services
🇺🇸
High Point, North Carolina, United States
Bellaire Dermatology
🇺🇸
Bellaire, Texas, United States
North Eastern Health Specialists
🇦🇺
Hectorville, South Australia, Australia
MUDr. Helena Korandova
🇨🇿
Olomouc, Czechia
Nemocnice Jihlava
🇨🇿
Jihlava 1, Czechia
Sinclair Dermatology
🇦🇺
East Melbourne, Victoria, Australia
University of British Columbia
🇨🇦
Vancouver, British Columbia, Canada
Sanatorium profesora Arenbergera
🇨🇿
Praha 1, Czechia
Dermatology Ottawa Research Centre
🇨🇦
Ottawa, Ontario, Canada
Terveystalo Tampere
🇫🇮
Tampere, Finland
Mehilainen Turku
🇫🇮
Turku, Finland
Local Institution - 0197
🇫🇮
Vaasa, Finland
Centre Hospitalier Regional Universitaire Brest Hopital Morvan
🇫🇷
Brest Cedex, France
Local Institution - 0128
🇩🇪
Augsburg, Germany
Harzklinikum Dorothea Christiane Erxleben
🇩🇪
Quedlinburg, Germany
CentroDerm GmbH
🇩🇪
Wuppertal, Germany
Debreceni Egyetem Klinikai Kozpont
🇭🇺
Debrecen, Hungary
Semmelweis Egyetem
🇭🇺
Budapest, Hungary
Synexus Magyarorszag Egeszsegugyi Szolgaltato - Debrecen Affiliated Site
🇭🇺
Debrecen, Hungary
Pecsi Tudomanyegyetem Klinikai Kozpont
🇭🇺
Pecs, Hungary
Szegedi Tudomanyegyetem
🇭🇺
Szeged, Hungary
Synexus Magyarorszag Egeszsegugyi Szolgaltato Kft. - Affiliated Site Gyula
🇭🇺
Gyula, Hungary
Allergo-Derm Bakos
🇭🇺
Szolnok, Hungary
Zespol Naukowo-Leczniczy Iwolang
🇵🇱
Iwonicz-Zdroj, Poland
Dermoklinika Centrum Medyczne S.C. M. Kierstan, J. Narbutt, A. Lesiak
🇵🇱
Lodz, Poland
ETG - Siedlce
🇵🇱
Siedlce, Poland
Local Institution - 0156
🇪🇸
Cordoba, Spain
Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego
🇵🇱
Warszawa, Poland
ProbarE i Lund
🇸🇪
Lund, Sweden
Ashgate Medical Practice
🇬🇧
Chesterfield, United Kingdom
MAC Clinical Research - Manchester
🇬🇧
Manchester, United Kingdom
Unity Clinical Research
🇺🇸
Oklahoma City, Oklahoma, United States
Oregon Dermatology and Research Center
🇺🇸
Portland, Oregon, United States
Hospital Universitario de Vinalopo
🇪🇸
Elche, Spain
Medical College of Wisconsin
🇺🇸
Milwaukee, Wisconsin, United States
Moore Clinical Research - South Tampa
🇺🇸
Tampa, Florida, United States
University of South Florida/USF Health
🇺🇸
Tampa, Florida, United States
ForCare Clinical Research
🇺🇸
Tampa, Florida, United States
Clintrial
🇨🇿
Praha 10, Czechia
Total Skin and Beauty Dermatology Center
🇺🇸
Birmingham, Alabama, United States
Center for Dermatology Clinical Research
🇺🇸
Fremont, California, United States
Anaheim Clinical Trials
🇺🇸
Anaheim, California, United States
Synexus Clinical Research - Saint Petersburg
🇺🇸
Pinellas Park, Florida, United States
Precision Clinical Research - Corporate Office
🇺🇸
Tamarac, Florida, United States
Dundee Dermatology
🇺🇸
West Dundee, Illinois, United States
Dermatology Center of Northwest Indiana
🇺🇸
Crown Point, Indiana, United States
ActivMed Practices and Research - Portsmouth
🇺🇸
Portsmouth, New Hampshire, United States
DermResearch Center of New York
🇺🇸
Stony Brook, New York, United States
Sadick Research Group
🇺🇸
New York, New York, United States
Wilmington Dermatology Center
🇺🇸
Wilmington, North Carolina, United States
Central Sooner Research
🇺🇸
Norman, Oklahoma, United States
Synexus
🇺🇸
Greer, South Carolina, United States
Modern Research Associates
🇺🇸
Dallas, Texas, United States
Synexus - Dallas
🇺🇸
Dallas, Texas, United States
Interspond - Houston Center for Clinical Research
🇺🇸
Sugar Land, Texas, United States
The Skin Centre
🇦🇺
Benowa, Queensland, Australia
Nemocnice Novy Jicin a.s.
🇨🇿
Novy Jicin, Czechia
Krajska zdravotni - Masarykova nemocnice v Usti nad Labem
🇨🇿
Usti nad Labem, Czechia
Kozni a zilni ambulance
🇨🇿
Usti nad Labem, Czechia
Fakultni Nemocnice Ostrava
🇨🇿
Ostrava, Czechia
Centre Hospitalier Universitaire de Toulouse- Hopital Larrey
🇫🇷
Toulouse Cedex 9, France
Hautarztpraxis Dr. Beatrice Gerlach
🇩🇪
Dresden, Germany
Local Institution - 0119
🇩🇪
Hamburg, Germany
Medizinische Hochschule Hannover
🇩🇪
Hannover, Germany
Dermakiel - Allergie Und Haut Centrum
🇩🇪
Kiel, Germany
Qualiclinic Egeszsegugyi Szolgaltato es Kutatasszervezo Kft.
🇭🇺
Budapest, Hungary
Praxis Dr. Beate Schwarz
🇩🇪
Langenau, Germany
Universitatsklinikum Schleswig-Holstein - Campus Lubeck
🇩🇪
Lubeck, Germany
Klinikum rechts der Isar der Technischen Universitat Munchen Klinik und Poliklinik fur Dermatolog
🇩🇪
Munchen, Germany
Praxis Dr. med. Wilfried Steinborn
🇩🇪
Straubing, Germany
Synexus Magyarorszag
🇭🇺
Budapest, Hungary
Local Institution
🇳🇿
Tauranga, New Zealand
ClinicMed Daniluk Nowak Spolka Jawna
🇵🇱
Bialystok, Poland
Synexus Polska Oddzial w Gdansk
🇵🇱
Gda?sk, Poland
Krakowskie Centrum Medyczne
🇵🇱
Krakow, Poland
Dermed Centrum Medyczne
🇵🇱
Lodz, Poland
Klinika Ambroziak
🇵🇱
Warsaw, Poland
Local Institution - 0142
🇵🇱
Torun, Poland
High-Med Przychodnia Specjalistyczna
🇵🇱
Warszawa, Poland
Hospital Universitario de Gran Canaria Doctor Negrin
🇪🇸
Las Palmas de Gran Canaria, Spain
Hospital Universitario Ramon Y Cajal
🇪🇸
Madrid, Spain
Local Institution - 0137
🇪🇸
Pozuelo de Alarcon, Spain
Hospital Universitario Virgen de la Victoria
🇪🇸
Mߧa, Spain
Hospital de Manises
🇪🇸
Manises, Spain
Burbage Surgery
🇪🇸
Santiago de Compostela, Spain
Consorci Hospital General Universitari de Valencia
🇪🇸
Valencia, Spain
Ladulaas Kliniska Studier
🇸🇪
Boras, Sweden
PharmaSite - Malmo
🇸🇪
Malmo, Sweden
MAC Clinical Research - Cannock
🇬🇧
Cannock, United Kingdom
Pharmasite - Helsingborg
🇸🇪
Helsingborg, Sweden
Karolinska Universitetssjukhuset
🇸🇪
Solna, Sweden
Local Institution - 0189
🇬🇧
Chorley, United Kingdom
Mounts Bay Medical
🇬🇧
Cornwall, United Kingdom
The Dudley Group NHS Foundation Trust
🇬🇧
Dudley, United Kingdom
MAC Clinical Research - Stockton
🇬🇧
Durham, United Kingdom
The Leeds Teaching Hospitals NHS Trust
🇬🇧
Leeds, United Kingdom
Skin Sciences
🇺🇸
Louisville, Kentucky, United States
DelRicht Research - New Orleans - Prytania Street
🇺🇸
New Orleans, Louisiana, United States
A. Alfred Taubman Health Care Center
🇺🇸
Ann Arbor, Michigan, United States
DermResearch
🇺🇸
Austin, Texas, United States
Applied Research Center of Arkansas
🇺🇸
Little Rock, Arkansas, United States
The Royal Melbourne Hospital
🇦🇺
Parkville, Victoria, Australia
Mediprobe Research
🇨🇦
London, Ontario, Canada
DermEffects
🇨🇦
London, Ontario, Canada
Montefiore Medical Center
🇺🇸
Bronx, New York, United States

Related News

jamanetwork.com

a month ago

Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis For Up to 3 Years

Deucravacitinib demonstrated consistent safety and maintained efficacy over 3 years in patients with moderate to severe plaque psoriasis, with no new safety signals observed compared to the first year of treatment.